Baidu
map

以病人为中心整合医疗资源——参观克利夫兰医学中心有感

2016-02-01 北京协和医院呼吸内科呼吸内科 侯小萌 医学论坛网

2014年,我受“百人计划”资助到美国的克利夫兰医学中心进行了参观学习,给我最深的感触就是这家医院以病人为中心整合医疗资源的管理理念。 克利夫兰医学中心(Cleveland Clinic Foundation,CCF)是美国顶尖综合医疗机构,成立于1921年,位于美国俄亥俄州的克利夫兰市,拥有医生3,000人,护士医生助理15,000人,全院职工43,000人,全美综合医院排名第四位。 初

2014年,我受“百人计划”资助到美国的克利夫兰医学中心进行了参观学习,给我最深的感触就是这家医院以病人为中心整合医疗资源的管理理念。

克利夫兰医学中心(Cleveland Clinic Foundation,CCF)是美国顶尖综合医疗机构,成立于1921年,位于美国俄亥俄州的克利夫兰市,拥有医生3,000人,护士医生助理15,000人,全院职工43,000人,全美综合医院排名第四位。

初到克利夫兰医学中心,首先吸引我的是她醒目的院标。这个院标代表着这家医学中心的办院理念“Patient First”精神,院标下面的注解是“每个生命都应当得到世界级的关爱”。基于此,医院自2004年开始进行了一系列管理创新,包括打破传统的专科管理模式,取消内外科的限制,相关专业集中起来,如创建了消化疾病中心、心血管疾病中心、呼吸疾病中心等。这种以患者为中心整合医疗资源的模式使病人就诊达到了最大的方便。

正是因为这种管理模式上的创新,克利夫兰诊所的心脏疾病中心、消化疾病中心、风湿免疫科、肾脏病中心、内分泌科、妇科、呼吸疾病中心等多个专科的排名均在全美名列前茅。

行政人员协作 体现人文关怀

克利夫兰诊所处处洋溢着医患和谐的氛围。走进它的接诊大厅,马上会被迎面扑来的艺术氛围感染,墙壁上悬挂着优雅的艺术作品,播放点里播放着悠扬的乐曲,人群川流却不拥挤。这时如果你停下来,只需要一个求助的眼神,随处可见的接诊人员就会友善地向你走来,并且认真负责地带你到达目的地。接诊人员除了这种负责引领到位的“红马甲”外,还有守在每幢建筑大门外负责代客泊车的“蓝马甲”。有了他们的帮助,即便背着氧气瓶独自开车来看病的病人也可以顺利从容地就诊。有时“蓝马甲”中的黑人小伙还会即兴在大厅中的钢琴上演奏一曲,让整个候诊区的气氛都活跃起来。在儿科候诊区的一角,你会看到社会工作者正站在盲人少年面前拉奏着小提琴,孩子认真倾听着乐曲,而母亲正在一旁微笑。这些接诊人员把温暖和关怀带给了来医院的每一个人。

事务性人员在医院员工总数里占有很大的比重,他们包括接诊人员、医生助理、预约人员、风险协调员(Risk manager)和事务协调员(Case manager)等。其中风险协调员是事务性人员中的高端组分,医院的各个视频播放点曾用一周的时间滚动播放着她们的照片名片,她们中的大部分人有法律和社会学的背景,是掌控医疗风险的天平。事务人员分布在与病人进行情感交流的第一线,构筑了医患之间的桥梁。他们的工作在疾病与医疗之间建立了“微笑”的缓冲地带,形成医生治“病”、服务人员关怀“人”的模式。


肺移植受试者筛选会议

克利夫兰诊所有着全美最好的肺移植中心之一。年移植病例数约100例,双肺移植的费用约为$500,000,移植后年花费约为$60,000。移植后1年生存率为83%,5年生存率为50%。肺移植的适应症包括特发性肺间质纤维化、慢性阻塞性肺疾病、囊性纤维化、肺动脉高压、间质性肺炎、结节病等等,几乎涵盖了呼吸系统所有慢性进展性疾病。事务人员与医疗人员的协作就突出体现在肺移植的受者筛选会议上(Recipients selection)。这是每周一早7点的例行会议,参加者包括呼吸内科医生、肺移植专业组医生、配型实验室人员、药师、感染科医师、风险协调员、社会工作者和胸外科医生。这场会议决定着列表上的哪一位患者会获得肺移植的机会。在呼吸内科负责医生和配型人员客观简洁地描述患者病情及配型方面的数据后,会议的主角登场了,她们就是风险协调员及事务协调员。她们在会议前与患者进行过详细的交流,对患者的家庭及社会情况作了详尽而客观的评价。在会议上她们会向全体参会者汇报患者本人及社会家庭的详尽信息,并对“病人”进行充分的评定,判断病“人”和其家庭能否耐受整个肺移植事件。她们的评价具有决定性,往往决定着患者能否获得肺移植的机会。只有通过这一关,外科医师、药师、感染科医师才会进一步讨论患者的手术、用药及预防性抗感染的方案。肺移植中心的负责人时刻提醒大家,肺移植的最大并发症不是死亡,而是患者家庭的全面破产。风险协调员所负的责任正是避免患者及其家庭走进“人财两空”的深渊,同时避免了医生在判断疾病的同时还要担心病人的人格承受力和经济承受力,规避了病人因为医生的拒绝产生的莫须有的怀疑和攻击。


医生守在多头显微镜旁

医疗协作保证精准诊断和诊治安全

每周四早7点是肺间质病专业组查房。参加人员包括提请查房的呼吸内科医生、肺间质病亚专业组、病理科肺部亚专业组和放射科肺部亚专业组。这种多科室共同讨论的模式被称为CPR模式。临床医生、放射科医生、病理科医生会分别给大家描述患者的临床特征、影像特征和组织特征,再根据自己专科的特点展开各自的诊断及鉴别诊断。最终,3个科室拟合出最恰当的结论。这种多元的病例分析使每个听众能够从刚才的病例临床特点展开的有关病理机制的想象,即刻就得到放射和病理的客观印证,每次都让我听得如痴如醉。

多科的医疗协作让诊治变得精准,病理科医生的“下临床”更让诊断变得高效。这里的病理科专家们经常出现在各个临床介入手术间的角落里、各个专业组病例讨论的会议上、各位临床专家们的开题会上。他们抱着一盒片子满处跑,有时自己都找不到回家的路,但他们却保证了临床医生在第一时间拿到最有力的诊断证据。原位细胞病理诊断是这家医院病理科工作的亮点。在介入支气管镜室的一个角落里放着一台多头显微镜,病理科医生就守在显微镜旁,介入手术间里,呼吸科医生正在给一位患者进行经支气管淋巴结穿刺(TBNA)的检查,每一针穿刺的组织都会被快速染色处理后送到手术间外的病理科医生那里作即时诊断。有时病理科医生告诉手术间内的操作者“这一针是坏死组织”,操作者就会及时修正穿刺手法;有时病理科医生的答案是这一针的组织非常好,已经可以诊断腺癌,并且组织足够送检下一步的分子病理检测了,那么操作者就会及时终止操作,避免了附加的风险和消耗。病理科医生常自豪地说,自从开展了原位病理诊断,病人“Recall”也就是二次上台的几率从原先的40%减少到了现在的5%。虽然病理科从事细胞病理的医生从6人扩招至13人,科内的支出有所增加,但病人的负担和医院的消耗却大大减少,因此被医院大力提倡和推广。

如果说病理科下临床给我的感受是震撼的话,那么药剂科下临床就只能让我眼巴巴地羡慕了。我印象中只在玻璃窗里面出现的药剂师,在这家诊所无处不在。每个普通病房、ICU、专业组查房都有他们的身影。他们或坐在固定终端旁,或手拿移动设备跟随查房队伍,不停核对每一位病人的医嘱,并根据每一位患者的既往病史、现病史、血相、肝肾功能和目前状态判断临床医生的医嘱是否恰当。临床医生也会在用药上与药剂师及时沟通,有时有的问题药剂师当时不能给出答案,会当场在移动终端上查阅文献给出解读。只有看见他们盯住每一条医嘱的专注表情,才能体会到他们保证临床用药安全的责任感。

不断改良的诊疗流程

克利夫兰诊所拥有全美最好的介入支气管镜室。支撑这个支气管镜室的不是那些先进的设备,而是其先进的人员配置和协作以及先进的管理机制。一台介入支气管镜正在进行,台上有一名术者,一名助手,这似乎与其它支气管镜室没有区别,但他们右侧站着的是麻醉科的一线、二线,台下忙碌的是负责分拣标本的护士和病理科随时准备制片的助手。手术室门外,病理科的医生正在等待,还有一名巡台的护士长和一名物资协调员。这支庞大的队伍正有条不紊地为台上一名患者服务。支气管镜的操作有一套完善的流程,具体包括术前门诊、术前访视、术前核对、术中的配合、术后术者的总结、术后访视。除此以外,为了降低系统误差,管理者还制定了一整套风险及事故管理机制。每一位呼吸内科的术者都有一条学习曲线,根据学习曲线的分数判定该医生是否可以上台操作,如果学习曲线分数不够,再知名的专家也会被拒之门外。拒绝生手上台并不代表拒绝新手上台。相反,在这里一名普通的呼吸科Fellow经过短短2周的普通支气管镜培训就可以获得上手学习介入支气管镜的机会了。每月一次的事故分析会在免责的环境中进行。

先进的信息系统整合资源

克利夫兰的信息系统非常人性化和便利化,整个信息系统是由谷歌公司操刀建设,医生只要登录任何一部终端,就能看到总院和其他分院患者的全部信息。最让人叹为观止的是这里的终端数量。每位住院病人床前按1:1-2配备移动终端,可供医生和护士同时对患者进行操作,随行的药剂师和其他医师会手拿iPAD随时应用电子密码接入系统,获得患者的全部信息并对患者的诊疗进行核对和处理。这个系统的应答效率也非常高,往往一个邀请会诊的“PAGE”在查房中发出去,还没有查到第二个病人,会诊大夫就出现了。奥巴马对CCF的信息系统也评价颇高,将其视为全美医院信息化的标杆,还盛赞它以最低的成本提供了最高标准的医疗服务。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1735855, encodeId=ed6d1e3585562, content=<a href='/topic/show?id=f8022886617' target=_blank style='color:#2F92EE;'>#克利夫兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28866, encryptionId=f8022886617, topicName=克利夫兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=846834021388, createdName=s_pl2019, createdTime=Sat Sep 17 07:43:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346900, encodeId=f3ce1346900bf, content=<a href='/topic/show?id=a252351803c' target=_blank style='color:#2F92EE;'>#医疗资源#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35180, encryptionId=a252351803c, topicName=医疗资源)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Wed Feb 03 00:43:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62655, encodeId=fb1b6265518, content=希望能去, beContent=null, objectType=article, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:49:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62619, encodeId=fd5f62619ec, content=是啊!怎么比!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 22:32:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62588, encodeId=76c46258816, content=没法比, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Mon Feb 01 22:23:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62488, encodeId=6cf1624888e, content=不能比, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62489, encodeId=8f5162489a9, content=然并卵, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1735855, encodeId=ed6d1e3585562, content=<a href='/topic/show?id=f8022886617' target=_blank style='color:#2F92EE;'>#克利夫兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28866, encryptionId=f8022886617, topicName=克利夫兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=846834021388, createdName=s_pl2019, createdTime=Sat Sep 17 07:43:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346900, encodeId=f3ce1346900bf, content=<a href='/topic/show?id=a252351803c' target=_blank style='color:#2F92EE;'>#医疗资源#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35180, encryptionId=a252351803c, topicName=医疗资源)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Wed Feb 03 00:43:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62655, encodeId=fb1b6265518, content=希望能去, beContent=null, objectType=article, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:49:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62619, encodeId=fd5f62619ec, content=是啊!怎么比!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 22:32:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62588, encodeId=76c46258816, content=没法比, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Mon Feb 01 22:23:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62488, encodeId=6cf1624888e, content=不能比, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62489, encodeId=8f5162489a9, content=然并卵, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1735855, encodeId=ed6d1e3585562, content=<a href='/topic/show?id=f8022886617' target=_blank style='color:#2F92EE;'>#克利夫兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28866, encryptionId=f8022886617, topicName=克利夫兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=846834021388, createdName=s_pl2019, createdTime=Sat Sep 17 07:43:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346900, encodeId=f3ce1346900bf, content=<a href='/topic/show?id=a252351803c' target=_blank style='color:#2F92EE;'>#医疗资源#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35180, encryptionId=a252351803c, topicName=医疗资源)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Wed Feb 03 00:43:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62655, encodeId=fb1b6265518, content=希望能去, beContent=null, objectType=article, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:49:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62619, encodeId=fd5f62619ec, content=是啊!怎么比!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 22:32:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62588, encodeId=76c46258816, content=没法比, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Mon Feb 01 22:23:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62488, encodeId=6cf1624888e, content=不能比, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62489, encodeId=8f5162489a9, content=然并卵, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-01 vinson820801

    希望能去

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1735855, encodeId=ed6d1e3585562, content=<a href='/topic/show?id=f8022886617' target=_blank style='color:#2F92EE;'>#克利夫兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28866, encryptionId=f8022886617, topicName=克利夫兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=846834021388, createdName=s_pl2019, createdTime=Sat Sep 17 07:43:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346900, encodeId=f3ce1346900bf, content=<a href='/topic/show?id=a252351803c' target=_blank style='color:#2F92EE;'>#医疗资源#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35180, encryptionId=a252351803c, topicName=医疗资源)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Wed Feb 03 00:43:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62655, encodeId=fb1b6265518, content=希望能去, beContent=null, objectType=article, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:49:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62619, encodeId=fd5f62619ec, content=是啊!怎么比!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 22:32:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62588, encodeId=76c46258816, content=没法比, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Mon Feb 01 22:23:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62488, encodeId=6cf1624888e, content=不能比, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62489, encodeId=8f5162489a9, content=然并卵, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-01 dhzzm

    是啊!怎么比!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1735855, encodeId=ed6d1e3585562, content=<a href='/topic/show?id=f8022886617' target=_blank style='color:#2F92EE;'>#克利夫兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28866, encryptionId=f8022886617, topicName=克利夫兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=846834021388, createdName=s_pl2019, createdTime=Sat Sep 17 07:43:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346900, encodeId=f3ce1346900bf, content=<a href='/topic/show?id=a252351803c' target=_blank style='color:#2F92EE;'>#医疗资源#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35180, encryptionId=a252351803c, topicName=医疗资源)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Wed Feb 03 00:43:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62655, encodeId=fb1b6265518, content=希望能去, beContent=null, objectType=article, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:49:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62619, encodeId=fd5f62619ec, content=是啊!怎么比!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 22:32:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62588, encodeId=76c46258816, content=没法比, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Mon Feb 01 22:23:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62488, encodeId=6cf1624888e, content=不能比, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62489, encodeId=8f5162489a9, content=然并卵, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-01 收获你的美

    没法比

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1735855, encodeId=ed6d1e3585562, content=<a href='/topic/show?id=f8022886617' target=_blank style='color:#2F92EE;'>#克利夫兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28866, encryptionId=f8022886617, topicName=克利夫兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=846834021388, createdName=s_pl2019, createdTime=Sat Sep 17 07:43:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346900, encodeId=f3ce1346900bf, content=<a href='/topic/show?id=a252351803c' target=_blank style='color:#2F92EE;'>#医疗资源#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35180, encryptionId=a252351803c, topicName=医疗资源)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Wed Feb 03 00:43:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62655, encodeId=fb1b6265518, content=希望能去, beContent=null, objectType=article, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:49:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62619, encodeId=fd5f62619ec, content=是啊!怎么比!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 22:32:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62588, encodeId=76c46258816, content=没法比, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Mon Feb 01 22:23:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62488, encodeId=6cf1624888e, content=不能比, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62489, encodeId=8f5162489a9, content=然并卵, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-01 李继凯

    不能比

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1735855, encodeId=ed6d1e3585562, content=<a href='/topic/show?id=f8022886617' target=_blank style='color:#2F92EE;'>#克利夫兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28866, encryptionId=f8022886617, topicName=克利夫兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=846834021388, createdName=s_pl2019, createdTime=Sat Sep 17 07:43:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346900, encodeId=f3ce1346900bf, content=<a href='/topic/show?id=a252351803c' target=_blank style='color:#2F92EE;'>#医疗资源#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35180, encryptionId=a252351803c, topicName=医疗资源)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Wed Feb 03 00:43:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62655, encodeId=fb1b6265518, content=希望能去, beContent=null, objectType=article, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:49:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62619, encodeId=fd5f62619ec, content=是啊!怎么比!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 22:32:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62588, encodeId=76c46258816, content=没法比, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Mon Feb 01 22:23:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62488, encodeId=6cf1624888e, content=不能比, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62489, encodeId=8f5162489a9, content=然并卵, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:22:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-01 李继凯

    然并卵

    0

相关资讯

美国克利夫兰医院向同行分享其数据分析算法

美国克利夫兰医院步梅奥医院之后尘,在Apervita平台上分享了自己的医疗数据分析算法。你了解Apervita吗?Apervita(http://apervita.com)是一个分享平台,医务人员或医疗机构可以将自己的研究、分析成果在该平台上发布,同行可以分享或购买,使大量的原本停留在纸面上的、被束之高阁的,或被封闭在小范围的、研究论文、数据分析结果或最佳实践等能够在同行间分享、传播或复用,不仅发

克利夫兰诊所公布2014十大医学创新榜单出炉

        美国克利夫兰医学中心日前公布了十大医学创新研究,并预测这十项研究将对2014年医学领域产生重大的影响。排在首位的是一种仿生视网膜,它可以使近乎失明多年的患者恢复基本的视力。         该榜单从15

2016十大医疗创新——第十届医学创新峰会

2016年,什么技术最先进?什么医疗技术将为人类带来重大的作用并产生巨大影响?1.预防公共流行疾病的疫苗安全、高效和有效且用于预防突发流行疾病的疫苗排在首位。自2014年埃博拉疫情在非洲爆发,细菌脑膜炎球菌(B型脑膜炎球菌)在美国爆发以来,这项任务显得尤为重要和严峻。面对这两项突发流行疾病,医生、科学家、医药公司和政府机构需要新的疫苗问世以解决人们面临的重大疾病问题。2.基于基因组学的临床试验在研

Baidu
map
Baidu
map
Baidu
map